Trial Profile

Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Jul 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aclidinium bromide (Primary) ; Aclidinium bromide
Indications Chronic obstructive pulmonary disease
Focus Adverse reactions; Pharmacokinetics
Sponsors Almirall S.A.; Forest

Most Recent Events

31 May 2011 Results published in the Journal of Clinical Pharmacology.
21 Oct 2010 New trial record
22 Sep 2010 Results were presented at the 20th Annual Congress of the European Respiratory Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com